Alphanco Venture Corp. announced that it has closed its proposed "Qualifying Transaction", as defined under TSXV policies, being the acquisition of all of the outstanding shares of Marvel Biotechnology Inc. (Marvel Biotech) effective June 14, 2021. In connection with closing of the Qualifying Transaction, AVC has changed its name to Marvel Biosciences Corp. In connection with the Transaction, Marvel Biosciences Corp. board of directors has been reconstituted and is now comprised of the following individuals: The company appointed Preston J. Maddin as Chief Financial Officer.